MX2019011958A - Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye. - Google Patents
Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye.Info
- Publication number
- MX2019011958A MX2019011958A MX2019011958A MX2019011958A MX2019011958A MX 2019011958 A MX2019011958 A MX 2019011958A MX 2019011958 A MX2019011958 A MX 2019011958A MX 2019011958 A MX2019011958 A MX 2019011958A MX 2019011958 A MX2019011958 A MX 2019011958A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- fusion protein
- pharmaceutical composition
- natural killer
- composition including
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 210000000822 natural killer cell Anatomy 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 abstract 1
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una proteína de fusión para tratar cánceres, y sus usos. La proteína de fusión para prevenir o tratar cánceres de acuerdo con la presente invención incluye: un anticuerpo o fragmento del mismo que se une a un antígeno asociado a tumor; un enlazador; y un polipéptido de fusión que incluye una proteína inductora de células asesinas naturales de CXCL16. En consecuencia, cuando se coadministra con una célula asesina natural, que es un agente terapéutico de inmunocito, la proteína de fusión aumenta en gran medida la introducción de la célula asesina natural en un cáncer que expresa un antígeno específico y, por lo tanto, exhibe un efecto notable en la prevención o el tratamiento de cánceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170043988 | 2017-04-05 | ||
PCT/KR2018/004043 WO2018186706A1 (ko) | 2017-04-05 | 2018-04-05 | Nk 세포 활성화 융합 단백질, nk 세포 및 이들을 포함하는 약제학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019011958A true MX2019011958A (es) | 2019-12-11 |
Family
ID=63712339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019011958A MX2019011958A (es) | 2017-04-05 | 2018-04-05 | Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye. |
Country Status (12)
Country | Link |
---|---|
US (1) | US11655306B2 (es) |
EP (1) | EP3594242A4 (es) |
JP (1) | JP6933724B2 (es) |
KR (1) | KR102009040B1 (es) |
CN (1) | CN110573529A (es) |
AU (1) | AU2018248672B2 (es) |
BR (1) | BR112019020909A2 (es) |
CA (1) | CA3057989C (es) |
IL (1) | IL269801B2 (es) |
MX (1) | MX2019011958A (es) |
RU (1) | RU2740438C1 (es) |
WO (1) | WO2018186706A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114887080B (zh) * | 2020-12-08 | 2023-10-31 | 深圳瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
CN114588258B (zh) * | 2022-05-10 | 2023-04-25 | 中山大学 | Bmp9联合nk细胞和pd-l1抗体在制备肝癌药物方面的应用 |
CN116790616B (zh) * | 2023-07-07 | 2023-12-15 | 佛山科学技术学院 | 编码sCXCL16的基因及表达载体、制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004253770C1 (en) | 2003-07-02 | 2010-04-15 | Innate Pharma | PAN-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy |
CN101084014A (zh) * | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
CA3018525C (en) | 2005-07-01 | 2023-08-01 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
EP1945674A2 (en) | 2005-11-03 | 2008-07-23 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
US20100183516A1 (en) | 2007-07-25 | 2010-07-22 | Markus Ribbert | Self coupling recombinant antibody fusion proteins |
KR20090053222A (ko) | 2007-11-22 | 2009-05-27 | 한국생명공학연구원 | 체액 내 대장암 마커로서의 cxcl-16유전자 및 이를이용한 대장암의 진단 및 치료에의 용도 |
WO2009114110A1 (en) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
BR112012004387A2 (pt) * | 2009-08-28 | 2015-09-08 | Vlst Corp | anticorpos anticinas que se l igam a múltiplas quimiocinas cc. |
US9249204B2 (en) * | 2011-06-01 | 2016-02-02 | Jyant Technologies, Inc. | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
WO2012166588A2 (en) | 2011-06-01 | 2012-12-06 | Morehouse School Of Medicine | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
US9561275B2 (en) * | 2012-09-14 | 2017-02-07 | The Johns Hopkins University | Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing |
AU2013327136A1 (en) | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
JP6487328B2 (ja) * | 2012-11-08 | 2019-03-20 | アルブミディクス リミティド | アルブミン変異体 |
CN105518143B (zh) * | 2013-03-15 | 2020-02-21 | 北京凯得尔森生物技术有限公司 | 融合蛋白分子和它的使用方法 |
US20180153938A1 (en) | 2015-05-05 | 2018-06-07 | University Health Network | NK Cells and Antibodies for Cancer Treatment |
ES2958720T3 (es) * | 2015-06-10 | 2024-02-13 | Immunitybio Inc | Células NK-92 modificadas para tratar el cáncer |
JP7018387B2 (ja) | 2015-10-16 | 2022-02-10 | ルードヴィッヒ-マクシミリアン-ユニヴェルシタート ミュンヘン | 腫瘍標的療法のためのcxcr6形質導入t細胞 |
KR101732126B1 (ko) | 2015-11-05 | 2017-05-02 | 한국생명공학연구원 | 췌장암 치료용 융합 단백질 및 이의 용도 |
-
2018
- 2018-04-05 AU AU2018248672A patent/AU2018248672B2/en active Active
- 2018-04-05 JP JP2019554653A patent/JP6933724B2/ja active Active
- 2018-04-05 IL IL269801A patent/IL269801B2/en unknown
- 2018-04-05 BR BR112019020909-3A patent/BR112019020909A2/pt not_active Application Discontinuation
- 2018-04-05 CA CA3057989A patent/CA3057989C/en active Active
- 2018-04-05 CN CN201880025476.7A patent/CN110573529A/zh active Pending
- 2018-04-05 KR KR1020180039975A patent/KR102009040B1/ko active IP Right Grant
- 2018-04-05 MX MX2019011958A patent/MX2019011958A/es unknown
- 2018-04-05 US US16/500,051 patent/US11655306B2/en active Active
- 2018-04-05 RU RU2019135054A patent/RU2740438C1/ru active
- 2018-04-05 WO PCT/KR2018/004043 patent/WO2018186706A1/ko unknown
- 2018-04-05 EP EP18781754.9A patent/EP3594242A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018248672A1 (en) | 2019-11-14 |
IL269801B1 (en) | 2023-10-01 |
JP6933724B2 (ja) | 2021-09-08 |
IL269801A (es) | 2020-02-27 |
IL269801B2 (en) | 2024-02-01 |
BR112019020909A2 (pt) | 2020-05-12 |
CN110573529A (zh) | 2019-12-13 |
CA3057989A1 (en) | 2018-10-11 |
EP3594242A4 (en) | 2020-12-09 |
RU2740438C1 (ru) | 2021-01-14 |
KR102009040B1 (ko) | 2019-08-08 |
EP3594242A1 (en) | 2020-01-15 |
JP2020515624A (ja) | 2020-05-28 |
WO2018186706A1 (ko) | 2018-10-11 |
CA3057989C (en) | 2023-03-21 |
AU2018248672B2 (en) | 2021-09-30 |
KR20180113183A (ko) | 2018-10-15 |
US20200148786A1 (en) | 2020-05-14 |
US11655306B2 (en) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500750A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
MX2020011546A (es) | Anticuerpos anti-msr1 y metodos de uso de los mismos. | |
PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
PE20210375A1 (es) | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales | |
AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
MX2023004333A (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. | |
MX2019011958A (es) | Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye. | |
MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
MX2024002182A (es) | Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii). | |
MX2022006148A (es) | Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit. | |
MX2021004603A (es) | Dosificacion. | |
MX2020013450A (es) | Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés. | |
MX2021009189A (es) | Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer. | |
MX2021003756A (es) | Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos. | |
MX2017001983A (es) | Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos. | |
WO2018174408A8 (ko) | 항-dr5 항체 및 그의 용도 |